Search results
Showing 1 to 5 of 5 results for tarlatamab
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
In development Reference number: GID-TA11812 Expected publication date: TBC
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]
Awaiting development Reference number: GID-TA11977 Expected publication date: TBC
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]
Awaiting development Reference number: GID-TA11981 Expected publication date: TBC
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.